A recent study published in Epilepsy & Behavior highlighted anxiety and depression prevalence in patients with Epilepsy (AWE) and diabetes (DP). The study aimed to determine the prevalence of anxiety, substance use, and depression in patients with DP and AWE. 

The study included 143 patients. Pediatric endocrinologists and pediatric neurologists diagnosed the participants. The researchers performed the urine toxicology screening to detect substance use. The Adolescent Substance Abuse Questionnaire (ASQ-AV) and Depression, Anxiety, and Stress Scale-21 (DASS-21) were used to assess addiction and negative emotions. 

Results showed that between AWE and DP groups, no significant differences were reported in terms of demographic characteristics (gender, age, and disease duration), substance use (7 % vs. 1.4 %), depression (76.4 % vs. 73.2 %), and anxiety (68.1 % vs. 69.0 %). In the AWE group, a higher addiction propensity score was found compared to the DP group (p = 0.018).